Health AI Central
Share:
Peer-Reviewed Publication
Cancer Epidemiol Biomarkers Prev2026May 4, 2026Journal Article

Modeled sojourn time and sensitivity for detecting preclinical cancers retrospectively by a multi-cancer early detection test.

James Y Dai1, E Georg Luebeck2, William D Hazelton3, Christina A Clarke4, Earl Hubbell5, Alpa V Patel6
1Grail (United States) Menlo Park, California United States.
2Fred Hutchinson Cancer Center Seattle, Washington United States.
3Fred Hutchinson Cancer Center Seattle, WA United States.
4Grail (United States) Menlo Park, CA United States.
5Grail (United States) Menlo Park United States.
6American Cancer Society Kennesaw, GA United States.
PubMed DOI

Abstract

BACKGROUND: Blood-based multi-cancer early detection tests have potential for clinical benefit, but key performance metrics for cancer screening, such as sojourn time and sensitivity of these tests for detecting pre-clinical disease, are not yet known. METHODS: In a retrospective analysis of stored plasma samples in the American Cancer Society Cancer Prevention Study-3 (CPS-3), GRAIL's MCED test…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.